세계의 소화기 치료제 시장 : 의약품 유형별, 용도별, 유통 채널별 - 기회 분석 및 산업 예측(2023-2032년)

Gastrointestinal Therapeutics Market By Drug Class, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 8,053,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,492,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

소화기 치료제 시장은 제약 부문의 소화기 치료제 수요 증가로 인해 2023년부터 2032년까지 5.0%의 높은 성장률을 기록할 것으로 예상 - Allied Market ResearchAllied Market Research의 연구 '소화기 치료제 시장' 보고서에 따르면 소화기 치료제 시장은 2022년 395억 달러로 평가되었고, 2023년부터 2032년까지 연평균 복합 성장률(CAGR) 5%로 성장해 2032년에는 645억 달러에 달할 것으로 예상됩니다.

소화기 치료학은 소화관(GI)에 영향을 미치는 질병 및 상태의 진단, 치료 및 관리에 초점을 맞춘 의학 및 의료의 한 분야를 말합니다. 위식도역류질환(GERD), 염증성 장질환(IBD), 소화성 궤양, 설사 등 다양한 소화관 질환을 치료하기 위한 약물치료, 외과적 개입, 생활습관 개선, 식이 요법 등 다양한 의학적 접근법을 포함합니다. 이 분야는 위장 건강 문제를 경험하는 사람들의 증상을 완화하고, 치유를 촉진하고, 합병증을 관리하고, 전반적인 웰빙을 향상시키는 것을 목표로합니다.

소화기병학, 면역학, 미생물학 등의 분야에서 진행되고 있는 연구는 소화기 질환의 근본적인 원인과 메커니즘을 더 깊이 이해하는 데 기여하고 있습니다. 이러한 지식은 표적 치료와 보다 맞춤 치료 접근법의 개발로 이어집니다. 위식도역류질환(GERD), 염증성 장질환(IBD), 과민성대장증후군(IBS) 등 위장질환의 유병률 증가로 인해 위장치료제 시장이 크게 성장하고 있습니다. 예를 들어, 2022년 미국 생명공학정보센터(NCBI)에 따르면, 위식도역류질환(GERD)은 미국에서 가장 많이 진단되는 소화기 질환 중 하나로, 유병률이 20%에 달하며 직간접적인 비용으로 큰 경제적 부담이 되고 있습니다. 이 질환은 세계적으로 수백만 명에게 영향을 미치고 있어 효과적인 치료 옵션에 대한 수요가 급증하고 있으며, 이는 시장 성장의 원동력이 될 것으로 예상됩니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter의 Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 소화기 치료제 시장 : 약제 클래스별

• 개요
• 생물제제
• 플로톤 펌프 억제제
• 아미노 살리실산염
• 제산제
• 완하제
• H2 길항제
• 기타

제5장 소화기 치료제 시장 : 용도별

• 개요
• 염증성 장질환
  • 염증성 장질환 소화기 치료제 시장 : 유형별
• 위식도 역류증
• 소화성 궤양 질환
  • 소화성 궤양 질환 소화기 치료제 시장 : 유형별
• 과민성 장증후군
• 기타

제6장 소화기 치료제 시장 : 유통 채널별

• 개요
• 병원 약국
• 드럭스토어 및 소매 약국
• 온라인 공급업체

제7장 소화기 치료제 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카/중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카공화국
  • 기타

제8장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10개 기업의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제9장 기업 개요

• AbbVie Inc.
• AstraZeneca plc
• Pfizer Inc.
• Bayer AG
• Bausch Health Companies Inc.
• Takeda Pharmaceutical Company Limited
• Cosmo Pharmaceuticals
• Organon Group of Companies
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries Limited

LSH

영문 목차

영문목차

The Gastrointestinal Therapeutics Market is likely to experience a significant growth rate of 5.0% from 2023-2032 owing to increase in demand for gastrointestinal drugs from pharmaceutical sector - Allied Market Research. According to a new report published by Allied Market Research, titled, "Gastrointestinal Therapeutics Market," The gastrointestinal therapeutics market was valued at $39.5 billion in 2022, and is estimated to reach $64.5 billion by 2032, growing at a CAGR of 5% from 2023 to 2032. Gastrointestinal therapeutics refers to the branch of medicine and healthcare focused on the diagnosis, treatment, and management of disorders and conditions affecting the gastrointestinal (GI) tract. Gastrointestinal therapeutics involves a range of medical approaches, including medications, surgical interventions, lifestyle modifications, and dietary recommendations, aimed at addressing various GI disorders such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), peptic ulcers, diarrhea, and more. The field aims to alleviate symptoms, promote healing, manage complications, and improve overall well-being for individuals experiencing gastrointestinal health issues.

Ongoing research in fields such as gastroenterology, immunology, and microbiology contribute to a deeper understanding of the underlying causes and mechanisms of gastrointestinal disorders. This knowledge leads to the development of targeted therapies and more personalized treatment approaches. The gastrointestinal therapeutics market has experienced significant growth owing to the rise in prevalence of gastrointestinal disorders, such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS). For instance, according to the National Center for Biotechnology and Information (NCBI) in 2022, gastroesophageal reflux disease (GERD) is one of the most commonly diagnosed digestive disorders in the U.S. with a prevalence of 20%, resulting in a significant economic burden in direct and indirect costs. As these disorders affect millions of people worldwide, there is a surge in demand for effective therapeutic options, which is expected to drive market growth.

In addition, the development of biologic therapies has revolutionized the treatment landscape for gastrointestinal disorders, which further supports the market growth. Biologics, such as monoclonal antibodies and cytokine inhibitors, provide targeted interventions that modify the inflammatory processes associated with disorders such as Crohn's disease and ulcerative colitis. Furthermore, ongoing research and development activities in the field of gastrointestinal therapeutics contribute toward the market growth. Pharmaceutical companies, academic institutions, and research organizations invest in discovering and developing innovative therapies, improving treatment efficacy, and expanding the range of available gastrointestinal therapeutics. For instance, Inspirna, Inc. is conducting a phase 1 study of RGX-202-01 (Ompenaclid) as combination therapy in 2nd Line RAS mutant advanced colorectal cancer. Thus, a rise in ongoing research and development activities in the field of gastrointestinal therapeutics is expected to drive the market growth.

The gastrointestinal therapeutics market is segmented into drug class, application, distribution channel, and region. By drug class, the market is segregated into biologics, proton pump inhibitors, aminosalicylates, antacids, laxatives, H2 antagonists, and others. By application, the market is classified into inflammatory bowel disease, gastroesophageal reflux disease, peptic ulcer disease, irritable bowel syndrome, and others. The inflammatory bowel disease segment is further categorized into Crohn's disease and ulcerative colitis. The peptic ulcer disease segment further categorized into the gastric ulcer and duodenal ulcer. By distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Others).

Major key players that operate in the gastrointestinal therapeutics market are AbbVie Inc., Pfizer Inc., AstraZeneca plc, Bayer AG, Takeda Pharmaceutical Company Limited, Organon Group of Companies, Bausch Health Companies Inc., Cosmo Pharmaceuticals, Teva Pharmaceutical Industries Limited, and Bristol-Myers Squibb Company. Key players have adopted product launch, product approval, and clinical trial as key developmental strategies to improve the product portfolio of the gastrointestinal therapeutics market.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gastrointestinal therapeutics market analysis from 2022 to 2032 to identify the prevailing gastrointestinal therapeutics market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the gastrointestinal therapeutics market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global gastrointestinal therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Class

• Biologics
• Proton Pump Inhibitors
• Aminosalicylates
• Antacids
• Laxatives
• H2 Antagonists
• Others

By Application

• Inflammatory Bowel Disease
  • Type
  • Crohn's Disease
  • Ulcerative Colitis
• Gastroesophageal Reflux Disease
• Peptic Ulcer Disease
  • Type
  • Gastric Ulcer
  • Duodenal Ulcer
• Irritable Bowel Syndrome
• Others

By Distribution Channel

• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Providers

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Bayer AG
• Bausch Health Companies Inc.
• Cosmo Pharmaceuticals
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Limited
• AbbVie Inc.
• Organon Group of Companies
• Pfizer Inc.
• AstraZeneca plc
• Bristol-Myers Squibb Company

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Moderate bargaining power of suppliers
  • 3.3.2. Moderate threat of new entrants
  • 3.3.3. Moderate threat of substitutes
  • 3.3.4. Moderate intensity of rivalry
  • 3.3.5. Moderate bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Increase in prevalence of gastrointestinal diseases
    • 3.4.1.2. Rise in geriatric population
    • 3.4.1.3. Rise in number of product launches

• 3.4.2. Restraints
  • 3.4.2.1. Stringent government regulations toward approval of biosimilars
  • 3.4.2.2. Patent expiry of drugs

• 3.4.3. Opportunities
  • 3.4.3.1. Rise in R&D activities
  • 3.4.3.2. Growth opportunities in emerging markets

CHAPTER 4: GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Biologics
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Proton Pump Inhibitors
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Aminosalicylates
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Antacids
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country
• 4.6. Laxatives
  • 4.6.1. Key market trends, growth factors and opportunities
  • 4.6.2. Market size and forecast, by region
  • 4.6.3. Market share analysis by country
• 4.7. H2 Antagonists
  • 4.7.1. Key market trends, growth factors and opportunities
  • 4.7.2. Market size and forecast, by region
  • 4.7.3. Market share analysis by country
• 4.8. Others
  • 4.8.1. Key market trends, growth factors and opportunities
  • 4.8.2. Market size and forecast, by region
  • 4.8.3. Market share analysis by country

CHAPTER 5: GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Inflammatory Bowel Disease
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
  • 5.2.4. Inflammatory Bowel Disease Gastrointestinal Therapeutics Market by Type
• 5.3. Gastroesophageal Reflux Disease
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Peptic Ulcer Disease
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
  • 5.4.4. Peptic Ulcer Disease Gastrointestinal Therapeutics Market by Type
• 5.5. Irritable Bowel Syndrome
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country
• 5.6. Others
  • 5.6.1. Key market trends, growth factors and opportunities
  • 5.6.2. Market size and forecast, by region
  • 5.6.3. Market share analysis by country

CHAPTER 6: GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospital Pharmacies
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Drug Stores and Retail Pharmacies
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Online Providers
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: GASTROINTESTINAL THERAPEUTICS MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Drug Class
  • 7.2.3. Market size and forecast, by Application
  • 7.2.4. Market size and forecast, by Distribution Channel
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Drug Class
    • 7.2.5.1.2. Market size and forecast, by Application
    • 7.2.5.1.3. Market size and forecast, by Distribution Channel
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Drug Class
    • 7.2.5.2.2. Market size and forecast, by Application
    • 7.2.5.2.3. Market size and forecast, by Distribution Channel
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Drug Class
    • 7.2.5.3.2. Market size and forecast, by Application
    • 7.2.5.3.3. Market size and forecast, by Distribution Channel
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Drug Class
  • 7.3.3. Market size and forecast, by Application
  • 7.3.4. Market size and forecast, by Distribution Channel
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Drug Class
    • 7.3.5.1.2. Market size and forecast, by Application
    • 7.3.5.1.3. Market size and forecast, by Distribution Channel
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Drug Class
    • 7.3.5.2.2. Market size and forecast, by Application
    • 7.3.5.2.3. Market size and forecast, by Distribution Channel
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Drug Class
    • 7.3.5.3.2. Market size and forecast, by Application
    • 7.3.5.3.3. Market size and forecast, by Distribution Channel
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Drug Class
    • 7.3.5.4.2. Market size and forecast, by Application
    • 7.3.5.4.3. Market size and forecast, by Distribution Channel
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Drug Class
    • 7.3.5.5.2. Market size and forecast, by Application
    • 7.3.5.5.3. Market size and forecast, by Distribution Channel
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Drug Class
    • 7.3.5.6.2. Market size and forecast, by Application
    • 7.3.5.6.3. Market size and forecast, by Distribution Channel
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Drug Class
  • 7.4.3. Market size and forecast, by Application
  • 7.4.4. Market size and forecast, by Distribution Channel
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Drug Class
    • 7.4.5.1.2. Market size and forecast, by Application
    • 7.4.5.1.3. Market size and forecast, by Distribution Channel
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Drug Class
    • 7.4.5.2.2. Market size and forecast, by Application
    • 7.4.5.2.3. Market size and forecast, by Distribution Channel
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Drug Class
    • 7.4.5.3.2. Market size and forecast, by Application
    • 7.4.5.3.3. Market size and forecast, by Distribution Channel
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Drug Class
    • 7.4.5.4.2. Market size and forecast, by Application
    • 7.4.5.4.3. Market size and forecast, by Distribution Channel
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Drug Class
    • 7.4.5.5.2. Market size and forecast, by Application
    • 7.4.5.5.3. Market size and forecast, by Distribution Channel
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Drug Class
    • 7.4.5.6.2. Market size and forecast, by Application
    • 7.4.5.6.3. Market size and forecast, by Distribution Channel
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Drug Class
  • 7.5.3. Market size and forecast, by Application
  • 7.5.4. Market size and forecast, by Distribution Channel
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Drug Class
    • 7.5.5.1.2. Market size and forecast, by Application
    • 7.5.5.1.3. Market size and forecast, by Distribution Channel
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Market size and forecast, by Drug Class
    • 7.5.5.2.2. Market size and forecast, by Application
    • 7.5.5.2.3. Market size and forecast, by Distribution Channel
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Market size and forecast, by Drug Class
    • 7.5.5.3.2. Market size and forecast, by Application
    • 7.5.5.3.3. Market size and forecast, by Distribution Channel
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Market size and forecast, by Drug Class
    • 7.5.5.4.2. Market size and forecast, by Application
    • 7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. AbbVie Inc.
  • 9.1.1. Company overview
  • 9.1.2. Key Executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. AstraZeneca plc
  • 9.2.1. Company overview
  • 9.2.2. Key Executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. Pfizer Inc.
  • 9.3.1. Company overview
  • 9.3.2. Key Executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
• 9.4. Bayer AG
  • 9.4.1. Company overview
  • 9.4.2. Key Executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
• 9.5. Bausch Health Companies Inc.
  • 9.5.1. Company overview
  • 9.5.2. Key Executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
• 9.6. Takeda Pharmaceutical Company Limited
  • 9.6.1. Company overview
  • 9.6.2. Key Executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. Cosmo Pharmaceuticals
  • 9.7.1. Company overview
  • 9.7.2. Key Executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
• 9.8. Organon Group of Companies
  • 9.8.1. Company overview
  • 9.8.2. Key Executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
• 9.9. Bristol-Myers Squibb Company
  • 9.9.1. Company overview
  • 9.9.2. Key Executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. Teva Pharmaceutical Industries Limited
  • 9.10.1. Company overview
  • 9.10.2. Key Executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments

관련자료